- Home
- CURR vs NKTX Comparison
CURR vs NKTX Comparison
Compare CURR & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURR
- NKTX
- Stock Information
- Founded
- CURR 2013
- NKTX 2015
- Country
- CURR Singapore
- NKTX United States
- Employees
- CURR N/A
- NKTX N/A
- Industry
- CURR Business Services
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- CURR Consumer Discretionary
- NKTX Health Care
- Exchange
- CURR Nasdaq
- NKTX Nasdaq
- Market Cap
- CURR 151.4M
- NKTX 123.5M
- IPO Year
- CURR N/A
- NKTX 2020
- Fundamental
- Price
- CURR $1.64
- NKTX $2.15
- Analyst Decision
- CURR Strong Buy
- NKTX Strong Buy
- Analyst Count
- CURR 1
- NKTX 5
- Target Price
- CURR $3.50
- NKTX $13.50
- AVG Volume (30 Days)
- CURR 256.8K
- NKTX 541.2K
- Earning Date
- CURR 08-04-2025
- NKTX 11-06-2025
- Dividend Yield
- CURR N/A
- NKTX N/A
- EPS Growth
- CURR N/A
- NKTX N/A
- EPS
- CURR N/A
- NKTX N/A
- Revenue
- CURR $41,092,419.00
- NKTX N/A
- Revenue This Year
- CURR N/A
- NKTX N/A
- Revenue Next Year
- CURR $14.56
- NKTX N/A
- P/E Ratio
- CURR N/A
- NKTX N/A
- Revenue Growth
- CURR N/A
- NKTX N/A
- 52 Week Low
- CURR $0.33
- NKTX $1.31
- 52 Week High
- CURR $7.08
- NKTX $6.63
- Technical
- Relative Strength Index (RSI)
- CURR 47.65
- NKTX 49.60
- Support Level
- CURR $1.60
- NKTX $2.04
- Resistance Level
- CURR $1.80
- NKTX $2.19
- Average True Range (ATR)
- CURR 0.13
- NKTX 0.12
- MACD
- CURR -0.02
- NKTX -0.02
- Stochastic Oscillator
- CURR 26.37
- NKTX 27.16
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech pioneer dedicated to transforming financial services through artificial intelligence (AI). It empowers financial institutions with comprehensive AI solutions, including the SEAMLESS AI Call Centre and other AI-powered tools designed to reduce costs, increase efficiency, and boost customer satisfaction. The Company's digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 payment services, advancing financial access across underserved communities. It generates the majority of its geographic revenue from Malaysia.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.